Researchers at Stanford have established the safety and penetrance of the dopaminergic prodrug etilevodopa to prevent the progression of myopia ("nearsightedness"). In the past 50 years, myopia prevalence in the U.S.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.